<DOC>
	<DOCNO>NCT01432665</DOCNO>
	<brief_summary>The Lybrido study double-blind , randomize , placebo-controlled study 4-week baseline establishment period , 16 week treatment period follow period total 26 week study . Subjects randomly one seven treatment arm . The study investigate effective dose Lybrido increase number satisfactory sexual episode domestic set 210 healthy female subject hypoactive sexual desire disorder low sensitivity sexual cue ( 30 subject per group ) .</brief_summary>
	<brief_title>Lybrido Female Sexual Dysfunction</brief_title>
	<detailed_description />
	<mesh_term>Sexual Dysfunctions , Psychological</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>1 . Provision write informed consent 2 . Female 21 70 year age , inclusive , pre postmenopausal , HSDD ( comorbidity female sexual arousal disorder and/or female orgasmic disorder [ FOD ; secondary diagnosis ] allow ) . The diagnosis HSDD establish trained professional . 3 . Low sensitivity sexual cue 4 . Be involve stable relationship partner home majority study duration 5 . Healthy accord normal result medical history , physical examination , laboratory value , vital sign ; exception may make investigator considers abnormality clinically irrelevant 1 . Any underlying cardiovascular condition , include unstable angina pectoris , would preclude sexual activity 2 . History myocardial infarction , stroke , transient ischemic attack , lifethreatening arrhythmia within prior 6 month 3 . Uncontrolled atrial fibrillation/flutter screen significant abnormality observe electrocardiogram ( ECG ) 4 . Systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure &gt; 90 mmHg . For subject &gt; 60 year old without diabetes mellitus , familial hypercholesterolemia , cardiovascular disease : systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure &gt; 90 mmHg 5 . Systolic blood pressure &lt; 90 mmHg and/or diastolic blood pressure &lt; 50 mmHg 6 . Use oral contraceptive contain antiandrogens 7 . Use oral contraceptive contain 50 μg estrogen 8 . Positive test result Chlamydia gonorrhea 9 . Pregnancy intention become pregnant study ( Note : A urine pregnancy test perform woman prior administration study medication . ) 10 . Lactating delivery previous 6 month 11 . Significant abnormal pap smear previous 12 month 12 . History bilateral oophorectomy 13 . Other unexplained gynecological complaint , clinically relevant abnormal uterine bleeding pattern 14 . Liver and/or renal insufficiency ( aspartate aminotransferase alanine aminotransferase &gt; 3 time upper limit normal and/or glomerular filtration rate &lt; 29 mL/min base Cockcroft Gault formula ) 15 . Current clinically relevant endocrine disease uncontrolled diabetes mellitus 16 . Current clinically relevant neurological disease , opinion investigator , would compromise validity study result , could form contraindication sildenafil and/or testosterone use 17 . History hormonedependent malignancy 18 . Vision impairment , partial complete blindness color blindness 19 . Dyslexia 20 . Positive test result human immunodeficiency virus , hepatitis B , hepatitis C ( acute chronic hepatitis infection ) 21 . History ( childhood ) sexual abuse , opinion investigator , could negative psychological effect testosterone administer 22 . ( Treatment ) psychiatric disorder , opinion investigator , would compromise validity study result could contraindication sildenafil and/or testosterone use 23 . Current psychotherapeutic treatment female sexual dysfunction 24 . Current sexual disorder vaginismus dyspareunia accord Diagnostic Statistical Manual Mental Disorders , fourth edition ( text revision ) . 25 . A substance abuse disorder , opinion investigator , likely affect subject 's ability complete study precludes subject 's participation study ( Mild moderate alcohol consumption allow must stop 12 hour home measurement [ Stroop task ] . ) 26 . Positive test result illicit drug 27 . Use potent CYP3A4 inhibitor ( eg , ritonavir , ketoconazole , itraconazole clarithromycin , erythromycin saquinavir ) 28 . Use potent CYP3A4 inducer ( eg , carbamazepine , phenytoin , phenobarbital , St John‟s wort , rifampin ) 29 . Use nitrate nitric oxide donor compound 30 . Use selective serotonin reuptake inhibitor , tricyclic antidepressant , antidepressant 31 . Use medication interferes study medication ( eg , monoamine oxidase [ MAO ] inhibitor [ include classic MAO inhibitor linezolid ] ) 32 . Use medication ( include herb ) would compromise validity study result 33 . Use testosterone therapy within 6 month study entry 34 . Illiteracy , unwillingness , inability follow study procedure 35 . Participation clinical trial within last 30 day 36 . Any clinically significant abnormality condition , opinion investigator , might interfere participant‟s ability provide inform consent comply study instruction , compromise validity study result , contraindication sildenafil and/or testosterone use</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>HSDD</keyword>
</DOC>